Loading clinical trials...
Loading clinical trials...
A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis (RadiCal)
Conditions
Interventions
Biospecimen Collection
Bone Scan
+6 more
Locations
47
United States
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
UC San Diego Moores Cancer Center
La Jolla, California, United States
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
Rush MD Anderson Cancer Center
Chicago, Illinois, United States
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois, United States
Start Date
July 29, 2020
Primary Completion Date
October 1, 2026
Completion Date
October 1, 2026
Last Updated
April 13, 2026
NCT05969860
NCT06863311
NCT07123090
NCT06349642
NCT07300241
NCT05433142
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions